This inventor holds 7 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: University of Michigan. Active years: 2019-2025.
Company Filing History:
Years Active: 2019-2025
Title: Alexandr Kalinin: Innovator in Pharmacogenomics
Introduction
Alexandr Kalinin is a prominent inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of pharmacogenomics, holding a total of 7 patents. His work focuses on the intersection of artificial intelligence and drug response, aiming to enhance clinical decision-making and drug discovery processes.
Latest Patents
Kalinin's latest patents include groundbreaking methods and systems for the reconstruction of drug response and disease networks. These methods describe an integrated, multiscale artificial intelligence-based system that reconstructs drug-specific pharmacogenomic networks. The system utilizes features of the functional topology of the three-dimensional architecture of drug-modulated spatial contacts in chromatin space. His innovative approach allows for the discovery of drug pharmacogenomic networks through the selection of candidate SNPs by imputation and the use of machine learning and deep learning to determine predicted causality. This work is crucial for applications in clinical decision support, drug repurposing, and in silico drug discovery.
Another notable patent focuses on pharmacogenomic decision support for modulators of the NMDA, glycine, and AMPA receptors. This method identifies patients diagnosed with treatment-resistant depression, pain, or other clinical indications who may benefit from specific therapies. The methods provide personalized recommendations for medication dosage and frequency, enhancing the efficacy of treatments while minimizing adverse drug events.
Career Highlights
Kalinin is affiliated with the University of Michigan, where he continues to advance research in pharmacogenomics. His innovative work has positioned him as a leader in the field, contributing to the understanding of how genetic factors influence drug response.
Collaborations
He collaborates with notable colleagues, including Brian D Athey and Alex S Ade, further enriching his research endeavors and expanding the impact of his work in pharmacogenomics.
Conclusion
Alexandr Kalinin's contributions to pharmacogenomics through his innovative patents and research at the University of Michigan highlight his role as a key figure in advancing personalized medicine. His work not only enhances our understanding of drug interactions but also paves the way for more effective treatment strategies.